These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7681121)

  • 41. Dutasteride and prostate cancer.
    Garattini S; Bertele' V
    N Engl J Med; 2010 Aug; 363(8):794; author reply 794-6. PubMed ID: 20842790
    [No Abstract]   [Full Text] [Related]  

  • 42. Medical treatment of benign prostatic hyperplasia.
    Connolly SS; Fitzpatrick JM
    Postgrad Med J; 2007 Feb; 83(976):73-8. PubMed ID: 17308208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
    MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
    [No Abstract]   [Full Text] [Related]  

  • 44. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer.
    Presti JC; Fair WR; Andriole G; Sogani PC; Seidmon EJ; Ferguson D; Ng J; Gormley GJ
    J Urol; 1992 Oct; 148(4):1201-4. PubMed ID: 1383574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

  • 46. Benign prostatic hyperplasia: drug and nondrug therapies.
    Bruskewitz RC
    Geriatrics; 1992 Dec; 47(12):39-42, 45. PubMed ID: 1280242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation.
    Grino PB; Bruskewitz R; Blaivas JG; Siroky MB; Andersen JT; Cook T; Stoner E
    J Urol; 1993 Feb; 149(2):339-41. PubMed ID: 7678870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Finasteride: the first 5 alpha-reductase inhibitor.
    Sudduth SL; Koronkowski MJ
    Pharmacotherapy; 1993; 13(4):309-25; discussion 325-9. PubMed ID: 7689728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors.
    Gormley GJ
    J Cell Biochem Suppl; 1992; 16H():113-7. PubMed ID: 1283894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
    Chen HJ; Chen YR
    Zhonghua Nan Ke Xue; 2011 Jan; 17(1):63-7. PubMed ID: 21351536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
    Sun J; Xiang H; Yang LL; Chen JB
    Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
    Arena F
    Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
    Schmidt LJ; Tindall DJ
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
    Ravish IR; Nerli RB; Amarkhed SS
    Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Finasteride for benign prostatic hyperplasia.
    Blumenstein BA
    N Engl J Med; 1993 Feb; 328(6):443. PubMed ID: 7678438
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effect of finasteride and dutasteride on chromogranin A levels.
    Sciarra A; Salciccia S; Nesi G; Cattarino S; Alfarone A; Gentilucci A; Gentile V
    Anticancer Res; 2010 Nov; 30(11):4737-42. PubMed ID: 21115933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evolving role of 5-alpha reductase inhibitors in chemoprevention.
    White WM; Kim ED
    Nat Rev Clin Oncol; 2010 Sep; 7(9):487-8. PubMed ID: 20798697
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.